-
Mashup Score: 1Cell Therapy R&D Careers - 1 month(s) ago
Cell Therapy R&D Careers
Source: www.novonordisk.comCategories: General Medicine News, CardiologistsTweet
-
Mashup Score: 0News Details - 2 month(s) ago
Bagsværd, Denmark, 8 March 2024 – Novo Nordisk today announced that the US Food and Drug Administration (FDA) has approved a label expansion for Wegovy ® based on a supplemental New Drug Application (sNDA) for the indication of reducing ri sks of major adverse cardiovascular events (MACE) including cardiovascular death, non-fatal heart attack (myocardial infarction) or non-fatal stroke in adults with either overweight or obesity and established cardiovascular disease (CVD). The approval is based on the
Source: www.novonordisk.comCategories: General Medicine News, CardiologistsTweet-
Whoops, looks like this is the direct link! https://t.co/jTpYsSQdj0
-
-
Mashup Score: 81News Details - 2 month(s) ago
To see all the news please click on the button
Source: www.novonordisk.comCategories: General Medicine News, CardiologistsTweet-
SELECT trial: Among 17k w overweight/obesity (BMI >27) & CVD but w/o diabetes, semaglutide 2.4mg sc v placebo led to 20% reduction in MACE https://t.co/yiQRvpxv3W @novonordisk
-
-
Mashup Score: 275News Details - 2 month(s) ago
Bagsværd, Denmark, 5 March 2024 – Novo Nordisk today announced the headline results from the kidney outcomes trial FLOW. The announcement today foll ows the decision to stop the trial early due to efficacy, which was announced on 10 October 2023, based on a recommendation from an Independent Data Monitoring Committee. The double-blind trial compared injectable semaglutide 1.0 mg with placebo as an adjunct to standard of care for prevention of progression of kidney impairment and risk of kidney and
Source: www.novonordisk.comCategories: General Medicine News, General HCPsTweet-
Announcement from @novonordisk re the FLOW trial: Semaglutide reduced the risk of 50% decline in eGFR, kidney failure, or death due to kidney or cardiovascular disease by 24% Results to be presented this year by trial PI @VladoPerkovic & colleagues https://t.co/hZT4iPxRvl
-
-
Mashup Score: 5News Details - 4 month(s) ago
Novo Nordisk will stop the once-weekly injectable semaglutide kidney outcomes trial, FLOW, based on interim analysis Bagsværd, Denmark, 10 October 2023 – Novo Nordisk today an nounced the decision to stop the kidney outcomes trial FLOW (Effect of semaglutide versus placebo on the progression of renal impairment in people with type 2 diabetes and chronic kidney disease). The decision to stop the trial is based on a recommendation from the independent Data Monitoring Committee (DMC) concluding that the
Source: www.novonordisk.comCategories: General Medicine News, NephrologyTweet-
also @nephroseeker suggests the story of GLP-1 in CKD (if Kim K and Oprah take it, why should we be left behind?!) The FLOW press release https://t.co/PKapA4aIAb leading to dialysis stocks tanking No results yet, but good story? #TopNephrology
-
-
Mashup Score: 22News Details - 7 month(s) ago
To see all the news please click on the button
Source: www.novonordisk.comCategories: Expert Picks, Latest HeadlinesTweet-
3500 patient Flow Trial of #Semaglutide in diabetics with kidney disease stopped early due to effectiveness of drug in preventing progression of kidney disease. #annusmirabilis continues https://t.co/CwGbgHka3q
-
-
Mashup Score: 0News Details - 7 month(s) ago
To see all the news please click on the button
Source: www.novonordisk.comCategories: Cardiologists, Latest HeadlinesTweet-
Unstoppable #GLP1RA semaglutide ‼️ #FLOW, the kidney outcomes trial of once-weekly injectable semaglutide, has stopped early for overwhelming efficacy based on interim analysis. More protection for our patients. https://t.co/qGtV75oaxZ https://t.co/d6mFOIwnwf
-
-
Mashup Score: 7News Details - 7 month(s) ago
To see all the news please click on the button
Source: www.novonordisk.comCategories: Cardiologists, Latest HeadlinesTweet-
RT @Nephro_Sparks: Wow! FLOW stopped early for efficacy! Another huge win for CKD https://t.co/4ZFPYqoRiR
-
-
Mashup Score: 4News Details - 7 month(s) ago
Novo Nordisk will stop the once-weekly injectable semaglutide kidney outcomes trial, FLOW, based on interim analysis Bagsværd, Denmark, 10 October 2023 – Novo Nordisk today announced the decision to stop the kidney outcomes trial FLOW (Effect of semaglutide versus placebo on the progression of renal impairment in people with type 2 diabetes and chronic kidney disease). The decision to stop the trial is based on a recommendation from the independent Data Monitoring Committee (DMC) concluding that the
Source: www.novonordisk.comCategories: Cardiologists, Latest HeadlinesTweet-
After CREDENCE, DAPA-CKD, & EMPA-KIDNEY, FLOW is 4th RCT in CKD to be stopped early. All 4 RCTs are event-driven; 3 were stopped at 50-60% accrual of planned events. How many of planned 854 events accrued in FLOW? Last time a HF RCT was stopped early? https://t.co/poTq0xN8Lb
-
Kidney outcomes trial of the GLP-1RA semaglutide 💉in patients w/ T2D + CKD (FLOW) stopped early for efficacy https://t.co/Cp9qSax66Y https://t.co/3LncTHJRI7
-
-
Mashup Score: 144News Details - 7 month(s) ago
Novo Nordisk will stop the once-weekly injectable semaglutide kidney outcomes trial, FLOW, based on interim analysis Bagsværd, Denmark, 10 October 2023 – Novo Nordisk today announced the decision to stop the kidney outcomes trial FLOW (Effect of semaglutide versus placebo on the progression of renal impairment in people with type 2 diabetes and chronic kidney disease). The decision to stop the trial is based on a recommendation from the independent Data Monitoring Committee (DMC) concluding that the
Source: www.novonordisk.comCategories: Cardiologists, Latest HeadlinesTweet-
2023, the year the #GLP1RA semaglutide can’t lose! #FLOW, the kidney outcomes trial of once-weekly injectable semaglutide, has stopped early for overwhelming efficacy based on interim analysis Massive news, results in Q1 2024 https://t.co/NIwf8km7Oy https://t.co/deCTcdbxpe
-
A remarkable transformation of care for people with diabetes and kidney disease in less than a decade. Before? Limited to only to RAS blockade. Now? Combination therapy with: - RASi - SGLT2i - GLP-1 RA - ns-MRA 4 pillars of care for diabetes & CKD https://t.co/zHoEs9vx4E https://t.co/kFkcHHcUoy
-
Fortunately @novonordisk was watching the fallout on LinkedIn and had an opening in their cardiac cell therapy programme that I am now filling with a somewhat unique ability to contribute to the cells, the procedure & the patients https://t.co/t7vS0qBzR5 7/